Allovir inc

US StockHealth Care

ALVR AI Analysis Overview

Keys for Bullish View

  • Value≥4
  • Dividend≥2

Analysis Conclusion

The stock has a lower value rating; if aiming for value investing, existing long-term positions might require gradual reduction.

ALVR Current Performance

1.71%

Allovir inc

1.95%

Avg of Sector

0.87%

S&P500

Top 10 High Relevance to ALVR

  • QURE Uniqure nv
    Value 4Trend 1Swing Trading 2Whale Interest 3Dividend 1
    See more

ALVR Profile

AlloVir, Inc. is an allogeneic T cell immunotherapy company with a focus on restoring natural immunity against life-threatening viral diseases in pediatric and adult patients with weakened immune systems. The company's proprietary technology platforms leverage off-the-shelf, allogeneic, single- and multi-virus-specific T cells for patients with T cell deficiencies who are at risk from the life-threatening consequences of viral diseases. Its technology and manufacturing process enable the potential for the treatment and prevention of a spectrum of devastating viruses with each single allogeneic cell therapy. Its lead product candidate, posoleucel, is a multi-VST therapy that targets six viruses: adenovirus (BKV), cytomegalovirus (EBV), human herpesvirus 6 (HHV-6) and JC virus (JCV). Its proprietary VST manufacturing platform enables the rapid, robust and reproducible generation of single-virus and multi-virus specific cell therapeutic candidates for clinical use.

Price of ALVR